Entinostat’s China Phase 3 Shows PFS Benefit Without Confirmed OS Gain

Company EOC Pharma Event Type Peer-Reviewed Phase 3 Long-Term Follow-Up Modality Small molecule; oral class I HDAC and HDAC4 inhibitor (with exemestane) Asset Entinostat (plus exemestane) Target Class I histone deacetylases; HDAC4 Disease Area HR-positive, HER2-negative advanced breast cancer Summary Long-term results from a randomized,…